Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 1
1989 2
1991 1
1994 1
1998 1
2003 2
2004 1
2006 1
2007 2
2008 1
2009 1
2010 1
2011 1
2012 2
2013 1
2015 2
2018 2
2019 3
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A. Menzies D, et al. Among authors: Valiquette C. N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283. N Engl J Med. 2018. PMID: 30067931 Free article. Clinical Trial.
Safety and Side Effects of Rifampin versus Isoniazid in Children.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D. Diallo T, et al. Among authors: Valiquette C. N Engl J Med. 2018 Aug 2;379(5):454-463. doi: 10.1056/NEJMoa1714284. N Engl J Med. 2018. PMID: 30067928 Free article. Clinical Trial.
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Sterling TR, et al. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. N Engl J Med. 2011. PMID: 22150035 Free article. Clinical Trial.
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Villarino ME, et al. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. JAMA Pediatr. 2015. PMID: 25580725 Free PMC article. Clinical Trial.
Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial.
Oxlade O, Trajman A, Benedetti A, Adjobimey M, Cook VJ, Fisher D, Fox GJ, Fregonese F, Hadisoemarto P, Hill PC, Johnston J, Long R, Obeng J, Ruslami R, Valiquette C, Menzies D. Oxlade O, et al. Among authors: Valiquette C. BMJ Open. 2019 Mar 20;9(3):e025831. doi: 10.1136/bmjopen-2018-025831. BMJ Open. 2019. PMID: 30898826 Free PMC article.
The mTST - An mHealth approach for training and quality assurance of tuberculin skin test administration and reading.
Moayedi-Nia S, Barss L, Oxlade O, Valiquette C, Ly MX, Campbell JR, Lan Z, Nsengiyumva P, Fregonese F, Lisboa Bastos M, Sampath D, Winters N, Menzies D. Moayedi-Nia S, et al. Among authors: Valiquette C. PLoS One. 2019 Apr 17;14(4):e0215240. doi: 10.1371/journal.pone.0215240. eCollection 2019. PLoS One. 2019. PMID: 30995275 Free PMC article. Clinical Trial.
Serum lipids as biomarkers for therapeutic monitoring of latent tuberculosis infection.
Albanna AS, Bachmann K, White D, Valiquette C, Menzies D. Albanna AS, et al. Among authors: Valiquette C. Eur Respir J. 2013 Aug;42(2):547-50. doi: 10.1183/09031936.00064713. Eur Respir J. 2013. PMID: 23904552 Free article. Clinical Trial. No abstract available.
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Campbell JR, et al. Among authors: Valiquette C. Lancet Infect Dis. 2020 Mar;20(3):318-329. doi: 10.1016/S1473-3099(19)30575-4. Epub 2019 Dec 19. Lancet Infect Dis. 2020. PMID: 31866327
27 results
Jump to page
Feedback